Ropidoxuridine (IPdR) is an orally bioavailable prodrug of the radiosensitizer IUdR. It is a halogenated thymidine analog developed to enhance tumor cell sensitivity to radiation therapy in preclinical cancer research, with studies conducted both in vitro and in vivo.